International quality control survey of neurochemical dementia diagnostics

被引：85

作者：

Lewczuk, Piotr

Beck, Georg

Ganslandt, Oliver

Esselmann, Hermann

Deisenhammer, Florian

Regeniter, Axel

Petereit, Hela-Felicitas

Tumani, Hayrettin

Gerritzen, Andreas

Oschmann, Patrick

Schroeder, Johannes

Schoenknecht, Peter

Zimmermann, Klaus

Hampel, Harald

Buerger, Katharina

Otto, Markus

Haustein, Sabine

Herzog, Karin

Dannenberg, Rainer

Wurster, Ulrich

Bibl, Mirko

Maler, Juan Manuel

Reubach, Udo

Kornhuber, Johannes

Wiltfang, Jens

机构：

[1] Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, Mol Neurobiol Lab, D-91054 Erlangen, Germany

[2] Ctr Clin Neuroproteom, Erlangen, Germany

[3] Univ Erlangen Nurnberg, Dept Neurosurg, D-91054 Erlangen, Germany

[4] Univ Gottingen, Dept Psychiat & Psychotherapy, D-3400 Gottingen, Germany

[5] Innsbruck Med Univ, Dept Clin Neurol, Innsbruck, Austria

[6] Univ Basel Hosp, CH-4031 Basel, Switzerland

[7] Univ Cologne, Dept Neurol, D-5000 Cologne 41, Germany

[8] Univ Ulm, Dept Neurol, D-7900 Ulm, Germany

[9] Med Lab Bremen, Bremen, Germany

[10] Univ Giessen, Dept Neurol, Giessen, Germany

[11] Heidelberg Univ, Sect Geriatr Psychiat, Heidelberg, Germany

[12] Lab Praxis Dr Zimmermann Dr Piontek Dr Bochmann, Dresden, Germany

[13] Univ Munich, Dementia Res Sect, Munich, Germany

[14] Univ Munich, Memory Clin, Alzheimer Mem Ctr, Munich, Germany

[15] Univ Munich, Dept Psychiat, Geriatr Psychiat Branch, D-8000 Munich, Germany

[16] Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany

[17] Asklepios Fachklinikum Stadtroda, Synlab Liquorzentrum, Stadroda, Germany

[18] Lab Praxis Dessau, Dessau, Germany

[19] Hannover Med Sch, Dept Neurol, Neurochem Lab, Hannover, Germany

来源：

NEUROSCIENCE LETTERS | 2006年 / 409卷 / 01期

关键词：

Alzheimer's disease; cerebrospinal fluid; Tau; amyloid; quality control;

D O I：

10.1016/j.neulet.2006.07.009

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Currently, neurochemical dementia diagnostics (NDD) are increasingly entering routine clinical neurochemistry, offering improved early and differential diagnosis of dementias. However, there is an obvious lack of standardization in pre-analytical sample handling and systematic quality surveys. Therefore, in this study, 14 laboratories in Germany, Austria, and Switzerland were given aliquots of a human cerebrospinal fluid (CSF) sample, and were asked to measure Alzheimer's disease (AD) biomarkers (amyloid beta (A beta) peptides, total Tau protein, and phosphorylated Tau protein (P-tau(181P))) according to their routine protocols. Results: The inter-laboratory coefficients of variation of the results obtained by the laboratories participating in this study were in the range of 20-30%. Although the results of this quality control survey are promising, the quality of measurements has to be further optimized. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 4

页数：4

共 22 条

[1]

Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109

[2] Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice [J].

Andreasen, N ;

Minthon, L ;

Davidsson, P ;

Vanmechelen, E ;

Vanderstichele, H ;

Winblad, B ;

Blennow, K .

ARCHIVES OF NEUROLOGY, 2001, 58 (03) :373-379

[3] Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment:: Indication of carrier-mediated epitope masking of amyloid β peptides [J].

Bibl, M ;

Esselmann, H ;

Otto, M ;

Lewczuk, P ;

Cepek, L ;

Rüther, E ;

Kornhuber, J ;

Wiltfang, J .

ELECTROPHORESIS, 2004, 25 (17) :2912-2918

[4] CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia [J].

Bibl, M ;

Mollenhauer, B ;

Esselmann, H ;

Lewczuk, P ;

Klafki, HW ;

Sparbier, K ;

Smirnov, A ;

Cepek, L ;

Trenkwalder, C ;

Rüther, E ;

Kornhuber, J ;

Otto, M ;

Wiltfang, J .

BRAIN, 2006, 129 :1177-1187

[5] Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry [J].

Davidsson, P ;

Folkesson, S ;

Christiansson, M ;

Lindbjer, M ;

Dellheden, B ;

Blennow, K ;

Westman-Brinkmalm, A .

RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2002, 16 (22) :2083-2088

[6] High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype [J].

Galasko, D ;

Chang, L ;

Motter, R ;

Clark, CM ;

Kaye, J ;

Knopman, D ;

Thomas, R ;

Kholodenko, D ;

Schenk, D ;

Lieberburg, I ;

Miller, B ;

Green, R ;

Basherad, R ;

Kertiles, L ;

Boss, MA ;

Seubert, P .

ARCHIVES OF NEUROLOGY, 1998, 55 (07) :937-945

[7] Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF [J].

Hulstaert, F ;

Blennow, K ;

Ivanoiu, A ;

Schoonderwaldt, HC ;

Riemenschneider, M ;

De Deyn, PP ;

Bancher, C ;

Cras, P ;

Wiltfang, J ;

Mehta, PD ;

Iqbal, K ;

Pottel, H ;

Vanmechelen, E ;

Vanderstichele, H .

NEUROLOGY, 1999, 52 (08) :1555-1562

[8] Cerebrospinal fluid tau and β-amyloid in Alzheimer patients, disease controls and an age-matched random sample [J].

Ibach, Bernd ;

Binder, Harald ;

Dragon, Margarethe ;

PoIjansky, Stefan ;

Haen, Ekkehard ;

Schmitz, Eberhard ;

Koch, Horst ;

Putzhammer, Albert ;

Kluenemann, Hans ;

Wieland, Wolf ;

Hajak, Goeran .

NEUROBIOLOGY OF AGING, 2006, 27 (09) :1202-1211

[9]

*ISO, 1994, 5725I ISO

[10] Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau [J].

Lewczuk, P ;

Esselmann, H ;

Otto, M ;

Maler, JM ;

Henkel, AW ;

Henkel, MK ;

Eikenberg, O ;

Antz, C ;

Krause, WR ;

Reulbach, U ;

Kornhuber, J ;

Wiltfang, J .

NEUROBIOLOGY OF AGING, 2004, 25 (03) :273-281

← 1 2 3 →